Answers are grounded in this paper and cite their sources.
BACKGROUND: Alzheimer's disease (AD), the most common cause of dementia, is characterized by interacting pathological processes in which chronic neuroinflammation plays a central role. The gut-brain axis connects intestinal and central nervous system function through immune, neural, and metabolic pathways, yet how immune signaling integrates these pathways in AD remains unclear. Human milk oligosaccharides (HMOs) are structurally diverse bioactive glycans whose immunomodulatory properties extend beyond their prebiotic effects. This narrative review examines HMOs within a gut-immune-brain framework, proposing that neuroinflammation amplifies the interplay between gut-derived immune signals, amyloid-β and tau pathology, and neurodegeneration. METHODS: Relevant literature was retrieved from PubMed, Web of Science, and Scopus through January 2026. The review focused on English-language publications from 2010 onward, supplemented by earlier foundational studies that provided essential mechanistic or historical context. RESULTS: We synthesize evidence on immune communication along the gut-brain axis and examine how HMOs may influence this communication through microbiota-dependent effects and direct interactions with immune receptors. Particular attention is given to the relationships between HMO structure, receptor engagement, immune cell responses, and inflammatory signaling. These mechanisms provide a rationale for investigating whether HMOs can modify peripheral immune signals that contribute to neuroinflammation in AD. Throughout the review, findings from infant and other experimental settings are distinguished from evidence directly relevant to aging and AD. CONCLUSION: Research on HMOs in aging and AD remains insufficient: direct evidence from aged or AD models is scarce, human trials are lacking, infant physiology differs substantially from that of older adults, and the bioavailability of HMOs to the aged brain is still uncertain. We therefore delineate this translational gap and outline research strategies to address it. Collectively, this review provides a conceptual framework for understanding the potential immunoregulatory roles of HMOs in neuroinflammation and identifies them as a hypothesis-generating class of candidate immunomodulators for AD.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: